NCT07401173Recruiting
DeepComp for Prediction of Gastric Cancer Postoperative Complications (DeepComp-Prospective)
A Prospective, Multicenter, Observational Study Validating the Multimodal Deep Learning Radiomics Model (DeepComp) for Preoperative Prediction of Major Postoperative Complications in Patients With Gastric Cancer
Source: ClinicalTrials.gov · Last updated 9 Apr 2026
Brief summary (registry, in English)
Gastric cancer is a leading cause of cancer-related mortality, and radical surgery remains the primary treatment. However, postoperative complications are common and can significantly impact patient recovery and quality of life. Currently, doctors lack precise tools to accurately predict which patients are at high risk for developing severe complications before surgery. This study aims to validate a novel artificial intelligence (AI) model called "DeepComp." The DeepComp model integrates clinical data with advanced radiomic features derived from routine preoperative CT scans. Specifically, it analyzes both the tumor characteristics and the patient's body composition (including skeletal muscle and fat distribution) to assess physiological reserve. In this prospective, multicenter observational study, researchers will enroll patients scheduled for gastric cancer surgery across five medical centers. The DeepComp model will be used to predict the risk of moderate-to-severe postoperative complications (Clavien-Dindo grade II or higher). These predictions will then be compared with the actual clinical outcomes observed 30 days after surgery. The goal is to determine the accuracy and reliability of the DeepComp model in a real-world clinical setting, potentially providing a powerful tool for personalized surgical risk assessment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 3 Feb 2026
- Start date
- 1 Mar 2026
- Primary completion date
- 1 May 2026
- Lead sponsor
- Qun Zhao
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07401173
What you commit to
- Study type: Observational
- Planned participants: 500
- From 1 Mar 2026 to the primary completion date, 1 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Emergency surgery due to perforation, obstruction, or massive bleeding.
- Intraoperative findings of distant metastasis (Stage IV) or unresectable disease preventing R0 resection.
- Concurrent or previous malignant tumors within the last 5 years (except gastric cancer).
Other
- Pregnancy or lactation.
- Severe metallic artifacts on CT images preventing radiomic analysis.
Who the study is looking for
- Age ≥ 18 years.
- Histologically confirmed gastric adenocarcinoma.
- Scheduled for elective radical gastrectomy (open, laparoscopic, or robotic) with curative intent.
- Standard preoperative contrast-enhanced abdominal CT scans (venous phase) performed within 14 days prior to surgery.
- Willingness to sign informed consent.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Fourth Hospital of Hebei Medical University Coordinator of this site? Confirm its status | Shijiazhuang | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.